[Ticlopidine and platelet function].
In macular degeneration disease of the eye, we have studied the behaviour of vitro thrombocyte aggregation/deaggregation and ex vivo plasma beta-thromboglobulin level (Born aggregometer, RIA kit) during administration of an antiaggregant platelet drug (ticlopidine). We have observed the presence of a prothrombotic state that improves after 15 days of administration of drug. In fact platelet aggregation and beta-thromboglobulin level significantly decrease while thrombocyte deaggregation significantly increase. The correlations between deaggregation, aggregation and beta-thromboglobulin level suggest that the antiaggregant action of the ticlopidine is linked to the inhibition of platelet release reaction.
Camici
M
M
Istituto Clinica Medica II, Università degli Studi, Pisa.
Evangelisti
L
L
D000328:Adult; D000368:Aged; D001792:Blood Platelets / Q000187:drug effects* / Q000502:physiology; D002214:Capsules; D005260:Female; D006801:Humans; D008268:Macular Degeneration / Q000097:blood / Q000188:drug therapy / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D010314:Partial Thromboplastin Time; D010974:Platelet Aggregation / Q000187:drug effects; D010976:Platelet Count / Q000187:drug effects; D012044:Regression Analysis; D013988:Ticlopidine / Q000008:administration & dosage*; D013997:Time Factors; D001620:beta-Thromboglobulin / Q000032:analysis / Q000187:drug effects
D002214:Capsules; D001620:beta-Thromboglobulin; D013988:Ticlopidine
Ticlopidina e funzione piastrinica.